Compared to healthy donor T cells, the baseline samples from CLL patients showed increased proliferation resulting in a decreased percentage of cells in early generations (generations 0–2) for CD4+ T cells which was corrected to healthy donor levels with ibrutinib treatment (Fig. 2C, D). This evidence concerns the gene CD4 and B-cell chronic lymphocytic leukemia.